Dr. Reddy’s launches Nexavar generic in the US

BL Hyderabad Bureau Updated - June 14, 2022 at 12:46 PM.
The Dr. Reddy’s Laboratories Ltd campus in Hyderabad | Photo Credit: KSL

Dr. Reddy’s Laboratories Ltd has launched sorafenib tablets, a therapeutic generic equivalent of Nexavar (sorafenib) in the US market following approval by the US Food and Drug Administration (USFDA). The drug is used to treat certain types of cancer. 

“We are pleased to launch this important generic product, illustrating our continued commitment to bring affordable generic medicines to market for patients,” Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories Inc, said in a release. 

The drug is available as 200 mg tablets in a bottle of 120.

Published on June 14, 2022 07:15

This is a Premium article available exclusively to our subscribers.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

You have reached your free article limit.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

You have reached your free article limit.
Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

TheHindu Businessline operates by its editorial values to provide you quality journalism.

This is your last free article.